June 17, 2020 / 11:31 AM / 22 days ago

BRIEF-Eli Lilly's Emgality Showed Reduction In Frequency, Duration And Migraine Pain Severity

June 17 (Reuters) - Eli Lilly and Co:

* EMGALITY® DEMONSTRATES REDUCTION IN FREQUENCY, DURATION, AND PAIN SEVERITY IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE

* ELI LILLY - PATIENTS ON EMGALITY EXPERIENCED STATISTICALLY FEWER SEVERITY-WEIGHTED HOURS OF PAIN THAN AT BASELINE AT EACH MONTH

* ELI LILLY - IN EPISODIC MIGRAINE, PATIENTS ON EMGALITY EXPERIENCED 68.6 FEWER SEVERITY-WEIGHTED HOURS OF PAIN PER MONTH ON AVERAGE THAN AT BASELINE

* ELI LILLY - IN CHRONIC MIGRAINE, PATIENTS ON EMGALITY EXPERIENCED 102.6 FEWER SEVERITY-WEIGHTED HOURS OF PAIN PER MONTH ON AVERAGE THAN AT BASELINE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below